Using MRI to assess penile cancer before surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of multi-parametric magnetic resonance imaging (mpMRI) in the preoperative assessment of patients with newly diagnosed penile squamous cell carcinoma (SCC). The study will include 60 patients referred to Oslo University Hospital for organ-sparing surgery (OSS), which may enhance quality of life and sexual function. By utilizing mpMRI, the researchers hope to improve patient selection and reduce the risk of local recurrence after surgery. The non-invasive nature of this imaging technique makes it a comfortable option for patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* newly diagnosed penile squamous cell carcinoma (SCC)
* the patient will benefit from organ-sparing surgery (OSS)
* signed broad consent for cancer research

Exclusion Criteria:

* N/A

Where it's running

• Oslo University Hospital
  Oslo, Norway Recruiting

Study contacts

• Principal investigator: Marta D Switlyk, MD PhD — Oslo University Hospital
• Study coordinator: Marta D Switlyk, MD PhD
• Email: marswi@ous-hf.no
• Phone: 47 915 02 770

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• EGFR-targeted therapy plus PD-1 blocker before surgery for advanced penile cancer

  This phase II trial tests whether Becotatug vedotin plus Pucotenlimab given before surgery can shrink tumors in men with advanced penile cancer and help preserve the penis when possible.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT07518979

• Beocotatug Vedotin plus Pucotenlimab for EGFR-positive advanced penile cancer

  This trial tests whether a targeted antibody-drug conjugate plus a PD-1 inhibitor can help people with EGFR-positive advanced penile cancer who have limited or no chemotherapy options.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07497919

• QL1706 with lenvatinib for previously treated penile cancer

  This trial tests whether combining QL1706 with lenvatinib can help control advanced or metastatic penile squamous cell carcinoma in people whose disease progressed after prior treatments.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07384416

• Comparing open and robot-assisted removal of groin lymph nodes for penile cancer

  This trial will test whether robot-assisted groin lymph node removal causes fewer complications and faster recovery than standard open surgery for men with penile squamous cell carcinoma who need lymphadenectomy.

  Recruiting at 8 sites University Hospital Tuebingen · Berlin and 8 other locations · NCT07378670

• MRG003 plus HX008 for EGFR-positive advanced or metastatic penile squamous cell carcinoma

  This trial tests whether combining the EGFR-targeted antibody-drug conjugate MRG003 with the PD-1 inhibitor HX008 works as a first-line treatment for men with EGFR-positive advanced or metastatic penile cancer.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07054307

• Treatment of rare advanced tumors with a combination of drugs

  This study is testing a new combination of drugs to see if it can help people with rare advanced tumors live longer and feel better.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06684327

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.